Bufo is a psychedelic drug derived from the venom of the Sonoran desert toad, a large amphibian found in the southwestern United States and northern Mexico. The active ingredient is a compound called 5-MeO-DMT, a powerful substance that produces an intense but short-lived psychedelic experience, typically lasting 5 to 30 minutes when inhaled as vapor. It is four to ten times more potent than DMT, the better-known psychedelic found in ayahuasca.
Where Bufo Comes From
The Sonoran desert toad (scientifically known as Incilius alvarius, formerly Bufo alvarius) produces a milky-white secretion from large glands behind its eyes called parotoid glands. This secretion contains 5-MeO-DMT along with several other bioactive compounds. To use it as a drug, the venom is collected from live toads, dried, and then vaporized and inhaled through a pipe or similar device.
The compound itself isn’t unique to toads. It was first isolated from the bark of a South American tree in 1959 and has been found in several plant species. But the toad venom became the most culturally prominent source, giving rise to the street name “Bufo” and the practice sometimes called “toad medicine” in ceremonial settings.
What the Experience Feels Like
When inhaled as vapor, the effects begin within about 5 to 10 seconds. That near-instant onset is one of the defining features of bufo, and it catches many people off guard. The peak experience is intense, often described as overwhelming, and the total duration of psychoactive effects runs roughly 5 to 30 minutes.
The hallmark psychological effect is ego dissolution: a feeling that the boundary between yourself and the rest of the world has dissolved. People describe this as a sense of oneness with the universe, a loss of personal identity, or a feeling of merging with everything around them. Unlike many other psychedelics, bufo typically produces these effects without strong visual hallucinations. Instead, the experience centers on distorted perception of time, amplified emotional states, and what researchers classify as mystical-type or “peak” experiences, including feelings of deep reverence, love, peace, and a sense that the experience is impossible to put into words.
The intensity of ego dissolution appears to matter. In observational studies, people who rated their ego dissolution as more intense also reported stronger long-term improvements in mental health afterward.
How It Works in the Brain
5-MeO-DMT floods the brain’s serotonin system. It activates serotonin receptors broadly but has especially high affinity for one particular receptor subtype (5-HT1A), which distinguishes it from most other psychedelics like LSD or psilocybin that work primarily through a different serotonin receptor. It also blocks serotonin from being reabsorbed by nerve cells, with a potency comparable to cocaine and methamphetamine in that specific action, though its overall effect profile is very different from stimulants. In laboratory measurements, it stimulates certain cell signaling pathways even more powerfully than serotonin itself.
Potential Effects on Depression and Anxiety
A survey of 362 people who had used 5-MeO-DMT in group settings found notable self-reported improvements. Among those who had been diagnosed with depression (41% of respondents), 80% said their depression improved after the experience. Among those diagnosed with anxiety (48% of respondents), 79% reported improvement. Only 3% said their depression worsened, and 2% said their anxiety worsened.
These improvements were linked to the intensity of the mystical experience. People who rated their experience as more spiritually significant and personally meaningful reported greater relief. Interestingly, having a physically or psychologically challenging time during the session itself did not predict worse outcomes. A phase 1/2 clinical trial has begun testing a pharmaceutical-grade vaporized formulation in patients with treatment-resistant depression, though this research remains early-stage.
Reactivations After Use
Some people report spontaneous “reactivations” in the days or weeks after using bufo, moments where elements of the psychedelic experience briefly return without taking the drug again. Common triggers include falling asleep, meditating, practicing relaxation techniques, or being in nature. In survey data, nearly all participants who experienced reactivations described them as positive or neutral rather than distressing. Researchers have speculated these episodes may actually contribute to the sustained antidepressant effects some users report, though this remains unproven.
Being female, older at first use, more educated, and using bufo in a structured group setting were all associated with higher odds of experiencing a reactivation. However, the number of lifetime doses or frequency of use did not increase the likelihood.
Physical Risks and Dangerous Interactions
Toad venom is not just 5-MeO-DMT. It contains a cocktail of other compounds, including bufadienolides, which are structurally similar to the heart medication digoxin. These compounds cause direct cardiac toxicity, including irregular heart rhythms and dangerously slowed heart rate, at very low concentrations.
The cardiac risks become especially dangerous when toad venom is combined with other substances. Certain heart and blood pressure medications can interact with bufadienolides in ways that worsen heart block and potentially fatal drops in heart rate, partly by increasing the amount of toxin absorbed by heart tissue. This makes bufo particularly risky for anyone taking cardiovascular medications.
The serotonin activity of 5-MeO-DMT also creates serious interaction risks with antidepressants, particularly MAOIs and other drugs that increase serotonin levels. Combining these can trigger serotonin syndrome, a potentially life-threatening condition.
Legal Status
5-MeO-DMT is a Schedule I controlled substance in the United States, meaning it is federally illegal to possess, distribute, or manufacture. It is also banned in the United Kingdom, Australia, and several other countries. However, the legal landscape around psychedelics is shifting. An increasing number of U.S. states and localities have changed or are considering changing their policies on certain psychedelic substances, though these reforms vary widely in scope and do not uniformly cover 5-MeO-DMT.
Conservation Concerns
The growing popularity of bufo has raised alarms about the Sonoran desert toad itself. While the species is still considered globally secure with a population numbering in the many thousands, it has experienced a long-term population decline of 30 to 50 percent. It has been nearly wiped out in California and carries a conservation ranking of “medium” threat level in parts of its range. The rising demand for toad venom has prompted some advocates to push for synthetic 5-MeO-DMT as an alternative, which would deliver the same compound without requiring toad capture. New Mexico, where the toad’s population is particularly vulnerable, lists the species as imperiled.